INVEST Revisited: Review of Findings from the International Verapamil SR–Trandolapril Study

Rhonda M Cooper-DeHoff; Eileen M Handberg; Giuseppe Mancia; Qian Zhou; Annette Champion; Udo F Legler; Carl J Pepine


Expert Rev Cardiovasc Ther. 2009;7(11):1329-1340. 

In This Article


Across the spectrum of hypertensive CAD patients studied in INVEST, we demonstrated that:

  • BP can be controlled in a high-risk population using a verapamil SR-based or an atenolol-based multi-drug treatment strategy without concern for safety or tolerance;

  • Lowering BP is associated with reduced risk of cardiovascular events, including all-cause death, MI and stroke;

  • Risk of new-onset diabetes is reduced when BP is lowered with the combination of verapamil SR plus trandolapril;

  • Both BP-lowering strategies reduce the occurrence of angina episodes, and this along with BP reduction is associated with improved feeling of well being.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: